UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.

@article{Schaik2009UGT1A9P,
  title={UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.},
  author={Ron H. N. van Schaik and Madelon van Agteren and Johannes W. de Fijter and Anders Hartmann and Justine R. Schmidt and Klemens Budde and Dirk Kuypers and Yannick Le Meur and Marloes van der Werf and Richard D. Mamelok and Teun van Gelder},
  journal={Clinical pharmacology and therapeutics},
  year={2009},
  volume={86 3},
  pages={319-27}
}
Mycophenolate mofetil (MMF) is an immunosuppressive drug commonly used in the context of kidney transplantation. Exposure to the active metabolite mycophenolic acid (MPA) is associated with risk of allograft rejection. MPA pharmacokinetics varies between individuals, the potential cause being the presence of genetic polymorphisms in key enzymes. We genotyped 338 kidney transplant patients for UGT1A8, UGT1A9, UGT2B7, and MRP2 polymorphisms and recorded MPA exposure and biopsy-proven acute… CONTINUE READING
32 Citations
48 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

a 5-year, open-label, prospective, clinical followup study in renal allograft recipients

  • Kuypers, D. R. et al. Current target ranges of mycophenolic ac exposure, drug-related adverse events
  • Clin. Ther. 30, 673–683
  • 2008

the fixed-dose concentration-controlled trial

  • van Gelder, T. et al. Comparing mycophenolate mofetil regimens fo recipients
  • Transplantation 86, 1043–1051
  • 2008

Similar Papers

Loading similar papers…